Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00539383 · ClinicalTrials.gov registry record · Phase 1
A Phase 1, Open-Label, Dose Escalation Study of ANG1005 in Patients With Advanced Solid Tumors and Metastatic Brain Cancer
A Phase 1 study of Advanced Solid Tumors With and Without Brain Metastases, sponsored by Angiochem.
- Completed
- Registry status
- Phase 1
- Development phase
- 56
- Enrollment target
- 3
- Study locations
NCT00539383: Completed Phase 1 study of Advanced Solid Tumors With and Without Brain Metastases, sponsored by Angiochem.
NCT00539383 is a Phase 1 study of Advanced Solid Tumors With and Without Brain Metastases that has completed, run by Angiochem. The registered enrollment target is 56 participants, roughly in line with the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target. The trial reports 3 study locations across 2 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00539383, a Phase 1 study of Advanced Solid Tumors With and Without Brain Metastases, has completed, sponsored by Angiochem.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 56 participants
- Enrollment target
- 3
- Study locations
Study Summary
This is a phase 1, multi-centre, sequential cohort, open-label, dose-escalation study of the safety, tolerability, and PK of ANG1005 in patients with solid tumors (with or without brain metastases). ANG1005 will be given by IV infusion once every 21 days (1 treatment cycle). Each patient will participate in only 1 dose group and will receive up to 6 cycles of treatment provided there is no evidence of tumor progression, there is recovery to ≤Grade 1 or baseline nonhematologic, ANG1005-related toxicity (except alopecia), the absolute neutrophil count is ≥1.5 x 109/L, and the platelet count is ≥100 x 109/L.
Conditions Studied
Interventions
- DRUG ANG1005
Study Locations (3)
Texas
- University of Texas, MD Anderson Cancer Center - Houston
- UT Health Science Center, Cancer Therapy and Research Center - San Antonio
Ohio
- Gabrail Cancer Center - Canton
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 56 participants |
| Start Date | 2007-10 |
| Est. Completion | 2010-03 |
| Phase | Phase 1 |
What the finished NCT00539383 record still lists
NCT00539383 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 56 participants, a relatively small participant target, roughly in line with the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target.
The record links to 1 condition, with Advanced Solid Tumors With and Without Brain Metastases appearing as the primary indexed condition, and to 1 intervention - of which ANG1005 is the first listed.
NCT00539383 reports a single indexed study location in Texas, Ohio.
Frequently Asked Questions
What is clinical trial NCT00539383 about?
NCT00539383 is a clinical study titled "A Phase 1, Open-Label, Dose Escalation Study of ANG1005 in Patients With Advanced Solid Tumors and Metastatic Brain Cancer". This is a phase 1, multi-centre, sequential cohort, open-label, dose-escalation study of the safety, tolerability, and PK of ANG1005 in patients with solid tumors (with or without brain metastases). ANG1005 will be given by IV infusion once every 21 days (1 treatment cycle). Each patient will partic...
What is the current status of trial NCT00539383?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 56 participants. The study started on 2007-10. Estimated completion is 2010-03.
What conditions does trial NCT00539383 study?
This clinical trial studies the following conditions: Advanced Solid Tumors With and Without Brain Metastases.
What interventions are being tested in trial NCT00539383?
The interventions under investigation include: ANG1005 (DRUG).
Who is sponsoring clinical trial NCT00539383?
This trial is sponsored by Angiochem, which has 6 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00539383 being conducted?
This trial has 3 study locations across Ohio, Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00539383's enrollment target sits among peer trials
56 902nd of 2000 higher than 1,083 of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02287428 · 56 participants · Phase 1
Personalized NeoAntigen Cancer Vaccine w RT Plus Pembrolizumab for Patients With Newly Diagnosed GBM
- NCT02923011 · 56 participants · Phase 3
Comparative Effectiveness of MRgFUS Versus CTgRFA for Osteoid Osteomas
- NCT02935283 · 56 participants
Neuroimaging and Neuropsychological Outcomes in Urea Cycle Disorders
- NCT03375866 · 56 participants · NA
Effects of Mixed Nut Consumption on Satiety and Weight Management
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia